The United States Food and Drug Administration (USFDA) has given tentative approval to Lupin for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine tablets, 50 mg/25 mg, to market a generic equivalent of Juluca tablets, 50 mg/25 mg of ViiV Healthcare, a statement from the company notified yesterday.

The tablets are used to treat HIV infection.
https://thehealthmaster.com/2023/01/17/usfda-gives-tentative-approval-for-dolutegravir-and-rilpivirine-tablets/